FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153670011> ?p ?o ?g. }

• W2153670011 endingPage "1893" @default.
• W2153670011 startingPage "1881" @default.
• W2153670011 abstract "Observational data and non-human primate challenge studies suggest that cell-mediated immune responses might provide control of HIV replication. The Step Study directly assessed the efficacy of a cell-mediated immunity vaccine to protect against HIV-1 infection or change in early plasma HIV-1 levels.We undertook a double-blind, phase II, test-of-concept study at 34 sites in North America, the Caribbean, South America, and Australia. We randomly assigned 3000 HIV-1-seronegative participants by computer-generated assignments to receive three injections of MRKAd5 HIV-1 gag/pol/nef vaccine (n=1494) or placebo (n=1506). Randomisation was prestratified by sex, adenovirus type 5 (Ad5) antibody titre at baseline, and study site. Primary objective was a reduction in HIV-1 acquisition rates (tested every 6 months) or a decrease in HIV-1 viral-load setpoint (early plasma HIV-1 RNA measured 3 months after HIV-1 diagnosis). Analyses were per protocol and modified intention to treat. The study was stopped early because it unexpectedly met the prespecified futility boundaries at the first interim analysis. This study is registered with ClinicalTrials.gov, number NCT00095576.In a prespecified interim analysis in participants with baseline Ad5 antibody titre 200 or less, 24 (3%) of 741 vaccine recipients became HIV-1 infected versus 21 (3%) of 762 placebo recipients (hazard ratio [HR] 1.2 [95% CI 0.6-2.2]). All but one infection occurred in men. The corresponding geometric mean plasma HIV-1 RNA was comparable in infected male vaccine and placebo recipients (4.61 vs 4.41 log(10) copies per mL, one tailed p value for potential benefit 0.66). The vaccine elicited interferon-gamma ELISPOT responses in 75% (267) of the 25% random sample of all vaccine recipients (including both low and high Ad5 antibody titres) on whose specimens this testing was done (n=354). In exploratory analyses of all study volunteers, irrespective of baseline Ad5 antibody titre, the HR of HIV-1 infection between vaccine and placebo recipients was higher in Ad5 seropositive men (HR 2.3 [95% CI 1.2-4.3]) and uncircumcised men (3.8 [1.5-9.3]), but was not increased in Ad5 seronegative (1.0 [0.5-1.9]) or circumcised (1.0 [0.6-1.7]) men.This cell-mediated immunity vaccine did not prevent HIV-1 infection or reduce early viral level. Mechanisms for insufficient efficacy of the vaccine and the increased HIV-1 infection rates in subgroups of vaccine recipients are being explored." @default.
• W2153670011 created "2016-06-24" @default.
• W2153670011 creator A5002030443 @default.
• W2153670011 creator A5004410155 @default.
• W2153670011 creator A5009619636 @default.
• W2153670011 creator A5011341715 @default.
• W2153670011 creator A5020047598 @default.
• W2153670011 creator A5025642389 @default.
• W2153670011 creator A5026975469 @default.
• W2153670011 creator A5035160383 @default.
• W2153670011 creator A5071619668 @default.
• W2153670011 creator A5073223457 @default.
• W2153670011 creator A5074227104 @default.
• W2153670011 creator A5075285906 @default.
• W2153670011 creator A5080589348 @default.
• W2153670011 creator A5080796048 @default.
• W2153670011 creator A5084520588 @default.
• W2153670011 creator A5085731242 @default.
• W2153670011 date "2008-11-01" @default.
• W2153670011 modified "2023-10-15" @default.
• W2153670011 title "Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial" @default.
• W2153670011 cites W133474286 @default.
• W2153670011 cites W1964552840 @default.
• W2153670011 cites W1967869186 @default.
• W2153670011 cites W1978584491 @default.
• W2153670011 cites W1979745197 @default.
• W2153670011 cites W1979754907 @default.
• W2153670011 cites W1980169905 @default.
• W2153670011 cites W1982767969 @default.
• W2153670011 cites W1991065985 @default.
• W2153670011 cites W1995300440 @default.
• W2153670011 cites W1998987175 @default.
• W2153670011 cites W2015283768 @default.
• W2153670011 cites W2026454199 @default.
• W2153670011 cites W2029043430 @default.
• W2153670011 cites W2032886698 @default.
• W2153670011 cites W2035053407 @default.
• W2153670011 cites W2037343680 @default.
• W2153670011 cites W2038114373 @default.
• W2153670011 cites W2047489384 @default.
• W2153670011 cites W2049025370 @default.
• W2153670011 cites W2051108441 @default.
• W2153670011 cites W2066142899 @default.
• W2153670011 cites W2067300626 @default.
• W2153670011 cites W2084534408 @default.
• W2153670011 cites W2088178092 @default.
• W2153670011 cites W2089650083 @default.
• W2153670011 cites W2105352387 @default.
• W2153670011 cites W2105809563 @default.
• W2153670011 cites W2108961890 @default.
• W2153670011 cites W2122715699 @default.
• W2153670011 cites W2124969212 @default.
• W2153670011 cites W2137903823 @default.
• W2153670011 cites W2138575726 @default.
• W2153670011 cites W2142916148 @default.
• W2153670011 cites W2144780961 @default.
• W2153670011 cites W2144882745 @default.
• W2153670011 cites W2151303894 @default.
• W2153670011 cites W2155612027 @default.
• W2153670011 cites W2158973015 @default.
• W2153670011 cites W2162891851 @default.
• W2153670011 cites W2166883229 @default.
• W2153670011 cites W2167594767 @default.
• W2153670011 cites W2170601880 @default.
• W2153670011 cites W2171754982 @default.
• W2153670011 cites W2172098972 @default.
• W2153670011 cites W2240372320 @default.
• W2153670011 cites W3209695718 @default.
• W2153670011 cites W4210762088 @default.
• W2153670011 cites W4248734872 @default.
• W2153670011 doi "https://doi.org/10.1016/s0140-6736(08)61591-3" @default.
• W2153670011 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2721012" @default.
• W2153670011 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19012954" @default.
• W2153670011 hasPublicationYear "2008" @default.
• W2153670011 type Work @default.
• W2153670011 sameAs 2153670011 @default.
• W2153670011 citedByCount "1551" @default.
• W2153670011 countsByYear W21536700112012 @default.
• W2153670011 countsByYear W21536700112013 @default.
• W2153670011 countsByYear W21536700112014 @default.
• W2153670011 countsByYear W21536700112015 @default.
• W2153670011 countsByYear W21536700112016 @default.
• W2153670011 countsByYear W21536700112017 @default.
• W2153670011 countsByYear W21536700112018 @default.
• W2153670011 countsByYear W21536700112019 @default.
• W2153670011 countsByYear W21536700112020 @default.
• W2153670011 countsByYear W21536700112021 @default.
• W2153670011 countsByYear W21536700112022 @default.
• W2153670011 countsByYear W21536700112023 @default.
• W2153670011 crossrefType "journal-article" @default.
• W2153670011 hasAuthorship W2153670011A5002030443 @default.
• W2153670011 hasAuthorship W2153670011A5004410155 @default.
• W2153670011 hasAuthorship W2153670011A5009619636 @default.
• W2153670011 hasAuthorship W2153670011A5011341715 @default.
• W2153670011 hasAuthorship W2153670011A5020047598 @default.
• W2153670011 hasAuthorship W2153670011A5025642389 @default.
• W2153670011 hasAuthorship W2153670011A5026975469 @default.
• W2153670011 hasAuthorship W2153670011A5035160383 @default.

• next